Core Insights - IR-MED is advancing its non-invasive, AI-powered infrared spectroscopy platform, PressureSafe™, aimed at assessing pressure injuries and diabetic ulcers, enhancing visibility in healthcare and investment communities [1][6]. Clinical Milestones - PressureSafe™ was presented at the Magnet & Pathway 2025 Conference, showcasing its effectiveness in assessing pressure injuries across diverse skin tones, particularly benefiting patients with darker skin [2]. - The clinical research highlighted the high sensitivity of near-infrared spectroscopy combined with AI, which aids in early detection of wounds, thereby improving patient outcomes [2]. Investment Engagement - At the NIBA Conference, IR-MED's executive team presented its diagnostic platform to public company executives and investment professionals, discussing progress towards commercialization and the potential to redefine non-invasive skin assessment [3][4]. Media Exposure - IR-MED's innovation was featured on Israel's Channel 10 program "The Next Big Thing," where the Co-Founder demonstrated how PressureSafe™ supports equitable wound care for all skin tones [5][6]. - The televised segment reached a nationwide audience in Israel, enhancing awareness of the company's mission to improve skin assessment and patient safety [6]. Product Overview - PressureSafe™ is designed to revolutionize the assessment of pressure injuries, which account for $26.8 billion in healthcare spending and 60,000 deaths annually in the U.S. alone [9]. - The device offers real-time evaluations of skin conditions, regardless of skin tone, addressing a significant healthcare challenge [9][10].